EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($2.15) for the year, down from their prior estimate of ($2.09). HC Wainwright has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals' Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.
EYPT has been the topic of several other reports. Jefferies Financial Group assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a "buy" rating and a $15.00 price target on the stock. Robert W. Baird lowered their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research note on Monday. Chardan Capital raised their price target on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research note on Saturday, September 21st. Finally, JPMorgan Chase & Co. cut their price objective on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, EyePoint Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $28.00.
Read Our Latest Analysis on EYPT
EyePoint Pharmaceuticals Price Performance
EYPT traded down $0.21 on Thursday, reaching $10.55. 341,520 shares of the company traded hands, compared to its average volume of 933,606. The company has a market cap of $564.64 million, a price-to-earnings ratio of -5.38 and a beta of 1.50. The stock's 50 day moving average price is $9.66 and its 200-day moving average price is $9.91. EyePoint Pharmaceuticals has a 52-week low of $5.86 and a 52-week high of $30.99.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its position in shares of EyePoint Pharmaceuticals by 44.0% in the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company's stock valued at $77,000 after acquiring an additional 1,136 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock valued at $82,000 after purchasing an additional 4,172 shares during the period. Greenwich Wealth Management LLC boosted its holdings in EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company's stock valued at $93,000 after purchasing an additional 900 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company's stock worth $95,000 after purchasing an additional 7,953 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC bought a new position in shares of EyePoint Pharmaceuticals during the 3rd quarter worth about $100,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.
About EyePoint Pharmaceuticals
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Featured Stories
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
